[1] Nakao T, Libby P.IL-6 helps weave the inflammatory web during acute coronary syndromes[J]. Journal of Clinical Investigation, 2023,133(11):4-8. [2] Wu HY, Gao TJ, Cao YW, et al.Analysis of the association and predictive value of hyperhomocysteinaemia for obstructive coronary artery disease[J]. Journal of International Medical Research, 2021,49(7):16812-16823. [3] International BM.Retracted: Predictive Significance of High-Sensitivity C-Reactive Protein Combined with Homocysteine for Coronary Heart Disease in Patients with Anxiety Disorders[J]. BioMed Research International, 2023,16(8):740-746. [4] 张可欣,赵雪燕. 血栓-炎症:冠心病抗栓治疗的新靶点[J]. 中华心血管病杂志,2024,52(10):1227-1234. [5] Repetenko M, Romanova V.Nonspecific systemic inflammation biomarkers as coronary heart disease destabilization criteria[J]. Atherosclerosis, 2024,399(6):476-502. [6] Yu Z, Zekavat SM, Honigberg MC, et al.Genetic IL-6 Signaling Modifies Incident Coronary Artery Disease Risk in Chronic KidneyDisease[J]. Journal of the American College of Cardiology, 2022,79(4):415-416. [7] 陈茗莉,郑群,马芳芳,等. 4种血清因子预测冠状动脉粥样硬化性心脏病发病的价值[J]. 中华高血压杂志,2022,30(11):1080-1084. [8] 张灵,袁小飞,李琦,等. 血清Hcy、 MTHFR基因多态性与血液病患者并发冠心病的相关性[J]. 中国实验血液学杂志,2022,30(1):305-309. [9] Ministrini S, Puspitasari YM, Han J, et al.Direct IL-6 inhibition prevents arterial thrombosis by reducing collagen-mediated platelets activation[J]. European Heart Journal, 2024,45(1):388-389. [10] 祖姆热提·阿布都克依木,马燕玲,朱凯瑞,等. 早期生长反应因子3和白介素6水平与冠状动脉粥样硬化性心脏病的相关性研究[J]. 中国全科医学,2023,26(24):3016-3021. [11] Jin P, Ma J, Wu P, et al.Mutual mediation effects of homocysteine and PCSK9 on coronary lesion severity in patients with acute coronary syndrome: interplay with inflammatory and lipid markers[J]. Lipids in Health and Disease, 2025,24(1):1-16. [12] 王晓雨,李冰,刘国晖. 炎症标志物在冠状动脉粥样硬化性心脏病诊断和治疗中应用的研究进展[J]. 吉林大学学报(医学版),2024,50(4):1173-1181. |